Russian government to introduce state regulation of drug prices in domestic market

27 October 2014

The Russian government is considering introducing state regulation of prices for drugs in the country, reports The Pharma Letter’s local correspondent.

It is planned that the new amendment may be included in the federal law "On the turnover of drugs," which might be approved by the Russian Parliament (State Duma) at the end of November.

In the event of approval of the amendment, the Russian government will start to analyze drug prices in foreign countries with the aim of further setting prices for them on the domestic market, based on the results of these analyses. According to state plans, this will help to avoid artificial increase of drug prices in the domestic market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK